Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Idexx Laboratories (IDXX)
NASDAQ:IDXX
IDXX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$398.50 - $583.39
Previous CloseN/A
Volume277.29K
Average Volume (3M)728.11K
Market Cap
$36.77B
Enterprise Value$34.70B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)42.3
Beta1.41
Next Earnings
Apr 30, 2025EPS Estimate
2.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.67
Shares Outstanding81,884,670
10 Day Avg. Volume628,788
30 Day Avg. Volume728,113
Standard Deviation0.10
R-Squared0.50
Alpha-0.00367
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.56
Price to Cash Flow (P/CF)41.80
P/FCF Ratio47.90
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.85
Enterprise Value/Ebitda27.67
Forecast
1Y Price Target
$518.57Price Target Upside14.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceIDEXX delivered a solid beat on the top and bottom line in Q4.
Market PositionIDEXX's conviction in its highly defensible leadership position and innovation drivers is intact in the attractive dog’nostics market longer term.
Product InnovationIDEXX expects to deliver over one point of revenue growth from its new InVueDx system and place 4,500 systems this year alone.
Bears Say
Growth Target ConcernsDespite contributions from multiple product cycles, organic sales growth in FY25 is projected to be around 7.5%, below the long-term target of 10%+.
Market SentimentPessimism stems from worries about declining visit volumes and a pet consumer that may be more financially squeezed, increased competition in the space, and questions over the trajectory of new drug and product launches.
Visit Volume DeclineContinued weakness of visit volumes in 4Q - particularly wellness - is a dynamic that will have to continue to be monitored.
---
Ownership Overview
0.96% Insiders
25.72% Mutual Funds
22.63% Other Institutional Investors
20.36% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IDXX FAQ
What was Idexx Laboratories’s price range in the past 12 months?
Idexx Laboratories lowest stock price was $398.50 and its highest was $583.39 in the past 12 months.
What is Idexx Laboratories’s market cap?
Idexx Laboratories’s market cap is $36.77B.
When is Idexx Laboratories’s upcoming earnings report date?
Idexx Laboratories’s upcoming earnings report date is Apr 30, 2025 which is in 68 days.
How were Idexx Laboratories’s earnings last quarter?
Idexx Laboratories released its earnings results on Feb 03, 2025. The company reported $2.62 earnings per share for the quarter, beating the consensus estimate of $2.403 by $0.217.
Is Idexx Laboratories overvalued?
According to Wall Street analysts Idexx Laboratories’s price is currently Undervalued.
Does Idexx Laboratories pay dividends?
Idexx Laboratories does not currently pay dividends.
What is Idexx Laboratories’s EPS estimate?
Idexx Laboratories’s EPS estimate is 2.86.
How many shares outstanding does Idexx Laboratories have?
Idexx Laboratories has 81,884,670 shares outstanding.
What happened to Idexx Laboratories’s price movement after its last earnings report?
Idexx Laboratories reported an EPS of $2.62 in its last earnings report, beating expectations of $2.403. Following the earnings report the stock price went up 11.134%.
Which hedge fund is a major shareholder of Idexx Laboratories?
Currently, no hedge funds are holding shares in IDXX
---
Idexx Laboratories Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$518.57 (14.98% Upside)
$518.57 (14.98% Upside)
Blogger Sentiment
Bullish
IDXX Sentiment 85%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.81%
12-Months-Change
Fundamentals
Return on Equity
57.66%
Trailing 12-Months
Asset Growth
1.03%
Trailing 12-Months
Company Description
Idexx Laboratories
Maine-based IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
---
IDXX Company Deck
---
IDXX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and growth across several segments, bolstered by successful product launches and international expansion. However, challenges such as a decline in US clinical visits and litigation expenses were noted. Overall, the positive aspects of IDEXX's performance and strategic advancements in innovation outweighed the challenges.Read More>---
IDXX Revenue Breakdown
65.32% U.S.
4.82% EMEA Other
4.10% Canada
4.09% Germany
21.67% Other
---
IDXX Stock 12 Month Forecast
Average Price Target
$518.57
▲(14.98% Upside)
Technical Analysis
Abbott Laboratories
―
Bio-Rad Laboratories
―
Petmed Express
―
Zoetis
―
Elanco Animal Health
―
Best Analysts Covering IDXX
1 Year
1 Year Success Rate
14/23 ratings generated profit
1 Year Average Return
+14.81%
reiterated a buy rating 19 days ago
Copying Erin Wright's trades and holding each position for 1 Year would result in 60.87% of your transactions generating a profit, with an average return of +14.81% per trade.
---